Title: Clinical study of continuous subcutaneous insulin infusion combined with rosiglitazone maleate in the intensive treating of type 2 diabetes mellitus
Abstract: Objective To evaluate the effect of continuous subcutaneous insulin infusion(CSⅡ) combined with rosiglitazone maleate (Ros M) on type 2 diabetic patients. Methods 246 patients with type 2 diabetes mellitus (T2DM) were divided into 3 groups randomly: CSⅡ combined with Ros M (n=80); simple CSⅡ (n=84); multiple deliver insulin (MDI) (n=82). The levels of blood glucose, HbA_1c, therapeutic time, amount of insulin, FIns, C-P, HOMA-IR and IAI were compared among them before and after 2 weeks of treatment. Results After treatment, compared with MDI group the two CSⅡ groups had lower levels of HbA_1c (7.0±1.2 and 7.2±1.2% vs 8.0±3.2%), therapeutic time (4.9±2.0 d and 5.1±1.8 d vs 10.5±3.7 d) and insulin amount (40.1±17.1 IU/d and 49.1±18.1 IU/d vs 54.1±18.2 IU/d) (all P0.01). The group of CSⅡ combined with Ros M showed the decreased HOMA-IR (0.72±0.28 vs 1.47±0.39) (P0.05) and increased IAI (-2.0±4.3 vs -3.6±4.2)(P0.05) and did not show the function impairments of heart, liver and kidney versus group of CSⅡ without Ros M treat. Conclusions CSⅡ combined with rosiglitazone maleate can improve the blood glucose and insulin resistance obviously.
Publication Year: 2006
Publication Date: 2006-01-01
Language: en
Type: article
Access and Citation
AI Researcher Chatbot
Get quick answers to your questions about the article from our AI researcher chatbot